ACRO Biomedical Co., Ltd.
TTPEX:6748185.00
TWD
-6.00
(-3.14%)
ISIN
TW0006748007
Return %
Stock
S&P 500
1Y
165.96
14.20
3Y
412.94
81.12
5Y
666.21
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Semi-annual Revenue
TWD
•
in mil. unless spec.Semi-annual Earnings Per Share
TWD
•
in mil. unless spec.Semi-annual Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Ta Jen Hsieh
- Full Time Employees
- 42
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- No.57, Luke 2nd Road Kaohsiung City KH Taiwan 82151
- IPO Date
- Jul 27, 2021
- Website
- acrobiomedical.com
- Similar Companies
- Business
- ACRO Biomedical Co., Ltd. develops and manufactures biomaterial medical devices specializing in human tissue engineering and regenerative medicine. The company’s core products include ABCcolla® Collagen Matrix for wound healing; ABCcolla® Bone Graft and Bone Matrix for orthopedic and dental bone repair promoting regeneration and vascularization; ABCcolla® Collagen Dermal Matrix (ADM) Scaffold for skin and soft tissue reconstruction; ABCcolla® Collagen Ophthalmic Matrix, a regenerative alternative to human corneal transplants; ACROTERM™ Scaffolds and Powders using porcine collagen for stem cell culture, tissue engineering, and 3D bioprinting; alongside wound care products and skin and eye care series. ACRO Biomedical applies proprietary supercritical carbon dioxide extraction technology to produce medical-grade collagen scaffolds, ensuring removal of cells and non-collagenous proteins while preserving the collagen structure for regenerative medical devices. Founded in Taiwan, where it is headquartered, ACRO Biomedical operates globally with regulatory approvals across multiple countries including Taiwan, Singapore, the Philippines, and markets in Australia and New Zealand via licensing agreements. The company serves medical segments such as orthopedics, dentistry, ophthalmology, cardiovascular, neural surgery, and aesthetic microsurgery. Recent major developments include gaining Taiwan Ministry of Health and Welfare approval for its Collagen Ophthalmic Matrix in 2025; securing Class III certification for multiple regenerative medical devices; expanded strategic partnerships including collaboration with Oculus Biomed Limited in Australia and a distribution alliance with DKSH; and a focus on advancing regenerative medicine technologies to address global tissue shortages. ACRO Biomedical also achieved significant growth recently, aiming for further expansion in regenerative medical device markets and published R&D advancements such as electro-optic collagen optimization and supercritical CO₂-processed biomaterials for wound healing and bone defect repair.